Here's what Wall Street expects from Eiger BioPharmaceuticals's earnings
Markets Insider Automation
Aug. 4, 2022, 09:01 AM
- Eiger BioPharmaceuticals reveals earnings for the most recent quarter on August 4.
- Wall Street analysts predict losses per share of $0.582.
- Track Eiger BioPharmaceuticals stock price in real-time on Markets Insider here.
On August 4, Eiger BioPharmaceuticals will release figures for Q2.
4 analysts are predicting losses of $0.582 per share compared to losses of $0.570 per share in the same quarter of the previous year.
Wall Street analysts are expecting the company to report $4.7 million, an increase of 123.81% over the prior year quarter when the company reported $2.1 million.
For the fiscal year, analysts expect a loss per share of $2.241, compared to $-1.000 in the same period last year. Sales estimates average $20.1 million, after the previous year saw $ 12.1 million.
This story was written by Markets Insider's RoboEddy, which automatically writes these stories based on data provided by our partners.